Boehringer Ingelheim GmbH, of Ingelheim, Germany, presented data from the phase III RE-DUAL PCI trial testing Pradaxa (dabigatran etexilate mesylate) and a single antiplatelet agent to vitamin K antagonist warfarin and two antiplatelets in 2,727 patients with nonvalvular atrial fibrillation who underwent percutaneous coronary intervention (PCI) with stenting.